Location of Repository

Rejection of large HPV-16 expressing tumors in aged mice by a single immunization of VacciMax<sup>® </sup>encapsulated CTL/T helper peptides

By MacDonald Lisa, Korets-Smith Ella, Fuentes-Ortega Antar, Pohajdak Bill, Mansour Marc, Daftarian Pirouz M, Weir Genevieve, Brown Robert G and Kast W Martin

Abstract

<p>Abstract</p> <p>The incidence of cancer increases significantly in later life, yet few pre-clinical studies of cancer immunotherapy use mice of advanced age. A novel vaccine delivery platform (VacciMax<sup>®</sup>,VM) is described that encapsulates antigens and adjuvants in multilamellar liposomes in a water-in-oil emulsion. The therapeutic potential of VM-based vaccines administered as a single dose was tested in HLA-A2 transgenic mice of advanced age (48–58 weeks old) bearing large palpable TC1/A2 tumors. The VM-based vaccines contained one or more peptides having human CTL epitopes derived from HPV 16 E6 and E7. VM formulations contained a single peptide, a mixture of four peptides or the same four peptides linked together in a single long peptide. All VM formulations contained PADRE and CpG as adjuvants and ISA51 as the hydrophobic component of the water-in-oil emulsion. VM-formulated vaccines containing the four peptides as a mixture or linked together in one long peptide eradicated 19-day old established tumors within 21 days of immunization. Peptide-specific cytotoxic cellular responses were confirmed by ELISPOT and intracellular staining for IFN-γ producing CD8<sup>+ </sup>T cells. Mice rendered tumor-free by vaccination were re-challenged in the opposite flank with 10 million HLF-16 tumor cells, another HLA-A2/E6/E7 expressing tumor cell line. None of these mice developed tumors following the re-challenge. In summary, this report describes a VM-formulated therapeutic vaccine with the following unprecedented outcome: a) eradication of large tumors (> 700 mm<sup>3</sup>) b) in mice of advanced age c) in less than three weeks post-immunization d) following a single vaccination.</p

Topics: Medicine (General), R5-920, Medicine, R, DOAJ:Medicine (General), DOAJ:Health Sciences
Publisher: BioMed Central
Year: 2007
DOI identifier: 10.1186/1479-5876-5-26
OAI identifier: oai:doaj.org/article:2bb062a709904a9984b802b39748090d
Journal:
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • https://doaj.org/toc/1479-5876 (external link)
  • http://www.translational-medic... (external link)
  • https://doaj.org/article/2bb06... (external link)
  • Suggested articles


    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.